Houston-based Cyberonics officials Thursday said the company could begin selling a more innovative version of its nerve-stimulating device to treat epilepsy as early as next spring, pending federal approval. President and CEO Dan Moore told analysts during Cyberonics’ quarterly earnings call he is hopeful the U.S. Food and Drug Administration, which regulates medical devices, will be satisfied with clinical trial results showing safety and effectiveness of the product, which is being used in Europe. However, the agency could require more testing, he said.
